CASE CCC IN THE NEWS
Taussig Cancer Institute is Giving Clinic's Reach a Big Lift
Crain's Business Cleveland - Sept 16, 2013
Enter Dr. Brian Bolwell, a roughly 25-year veteran of the Clinic, who quietly stepped into Taussig's leadership role on an interim basis. Despite the Clinic launching a national search for Dr. Raghavan's permanent successor, the health system chose to stick with Dr. Bolwell – and for good reason...Last year, Dr. Nathan Levitan, president of UH's Seidman Cancer Center, told Crain's the region's aging population was one of the main reasons UH was expanding its cancer program so heavily...One of Taussig's burgeoning research interests – and one of the Clinic's overall – is in the area of personalized medicine and genomics. Within the last month, one of Taussig's newest docs, Dr. Davendra Sohal, started enrolling patients in a new study that allows select cancer patients to have their tumors analyzed individually for genetic mutations that might avail them of new treatments.
Cleveland Clinic Starts Trial of Cancer Drug to Treat Alzheimer's Disease
The Plain Dealer - Sept 12, 2013
Researchers at the Cleveland Clinic are taking a small step forward in testing for the first time on people a promising treatment for Alzheimer's disease – a cancer drug that rapidly removed the damaging protein implicated in the progression of the illness from the brains of mice in early trials at Case Western Reserve University...The Clinic researchers are building off the work of Case neurosciences professor Gary Landreth and his former graduate student, Paige Cramer, who is currently employed at pharmaceutical giant Merck & Co.
OSU to Open New Triple Negative Breast Cancer Study; Cleveland Clinic, UH and 6 Others Also to Enroll Patients
The Plain Dealer - Sept 12, 2013
By the end of the month, the Ohio State University James Cancer Hospital will open a Phase 2 clinical trial to test two drugs for the treatment of triple negative breast cancer — a very aggressive type of cancer with high rates of recurrence...Up to 40 patients will be enrolled in the trial. Along with OSU, eight other sites across the country – including the Cleveland Clinic Taussig Cancer Instituteand University Hospitals Seidman Cancer Center — will offer the trial.
FDA Panel Backs Pre-Surgery Drug for Breast Cancer
New York Times - Sept 12, 2013
A federal advisory committee cleared the way on Thursday for the first approval of a cancer drug that would be used to treat patients before surgery to remove their tumors..."This is a historic moment," Dr. Mikkael A. Sekeres, an associate professor at the Cleveland Clinic who served as the chairman of the advisory committee, said immediately after the vote. "We are supporting the rapid movement of a highly active drug for metastatic cancer to the first-line setting, with the hope that women with earlier stages of breast cancer will live longer and better."
Biomarker May Predict Prostate Cancers Requiring Treatment
Cancer Network - Sept 11, 2013
Researchers at Columbia University in New York City have now identified a 3-gene signature that could indicate whether a particular early-stage prostate cancer is indolent. .."These types of markers will, for the first time, give us the opportunity to measure biological features of cancer in the same patient, with multiple biopsies spread out over many years," said Eric Klein, MD, chairman, Glickman Urological and Kidney Institute at the Cleveland Clinic in Ohio.
Affordable Care Act implementation looms amid hope, speculation
Helio/HemOnc Today - Sept 10, 2013
A fee-for-service model of health care delivery – rather than the fee-for-value model envisioned under the ACA – contributed significantly to skyrocketing costs, said Brian J. Bolwell, MD, FACP, chairman of Cleveland Clinic's Taussig Cancer Institute...
Research on Leptin Receptor Highlighted in Mammary Cell News
An article by Dr. Ofer Reizes, titled Leptin Receptor Maintains Cancer Stem-Like Properties in Triple Negative Breast Cancer Cells, was recently highlighted in "Mammary Cell News". The authors tested the hypothesis that the Leptin Receptor (LEPR), expressed in mammary cancer cells, is necessary for maintaining cancer stem cell-like and metastatic properties. They silenced LEPR via shRNA lentivirus transduction and determined that expression of stem cell self-renewal transcription factors NANOG, SOX2, and OCT4 are inhibited. Co-authors on the study include Qiao Zheng, Lauren Banaszak, Sarah Fracci, Diana Basali, Sarah M Dunlap, Stephen D Hursting, Jeremy N Rich, Anita B Hjelmeland, Amit Vasanji, Nathan A Berger, and Justin D Lathia.
MARK YOUR CALENDARS
Basic Sciences Program Mini-Retreat
The Basic Sciences Program, led by Drs. Clark Distelhorst and Alex Almasan, will be hosting a mini-retreat on Thursday, September 26 from 1-5 pm in WRB 3-136. The retreat will explain the restructuring of the program, feature short, informal presentations, and offer open time to discuss collaborations with other members. All members of the Basic Sciences Program are invited. Please RSVP by Monday, September 23 to firstname.lastname@example.org.
Society for Immunotherapy Regional Conference: Advances in Immunotherapy
The Society for Immunotherapy's regional Advances in Immunotherapy program will be held October 4 at the Intercontinental Hotel and Conference Center at Cleveland Clinic. This CME-accredited program, sponsored by Cleveland Clinic Center for Continuing Medical Education in collaboration with the Case Comprehensive Cancer Center, is specifically designed for the entire unit of care involved in treating cancer. Through several lectures by leading cancer immunologists, this program will summarize central themes in research advances and approvals to facilitate understanding of more sophisticated principles of tumor immunology and immunotherapy, and promote appropriate clinical application. Registration deadline is September 25.
Brain Tumor Funders' Collaborative
The Brain Tumor Funders' Collaborative (BTFC) funding initiative intends to support a fuller characterization of long term survivors based on the physiological, genetic, and molecular characteristics of not just the tumor, but of the entire organism in which a disease occurs (e.g. immunological changes, altered metabolism). The BTFC believes this broad, holistic approach is critical for understanding patient management and for informing clinical trial designs in the highly heterogeneous, noisy background against which interventions are tested. The complicated nature of the problem addressed by this BTFC initiative and the relatively small numbers of long-term survivors indicates to the BTFC that successful applications will require multi-institutional collaborations and extended community outreach accrual efforts.
LOI Deadline: October 1
Application Deadline: December 15
CTSC Child Health Themed Pilot Awards
The Clinical and Translational Science Collaborative (CTSC) at CWRU seeks applications for pilot research funding from faculty at CWRU, Cleveland Clinic, Metro Health Medical Center, University Hospitals Case Medical Center, and the Louis Stokes Veterans' Administration Medical Center. The primary goal of the Child Health Themed Pilot Award is to support and encourage collaborative research in clinical and translational medicine focused on child health that will lead to both external funding opportunities and new discoveries that will promote and advance child health.
Deadline: October 1
Clinical Assay Development Program
The NCI Clinical Assay Development Program (CADP) is accepting applications from investigators seeking clinical assay development and validation resources. These resources are designed to assist with the development of assays that may predict therapy response or prognostic behavior of a diagnosed cancer, primarily for use in clinical trials. In addition to access to the Institute's assay and validation resources, approved projects will receive project management support.
Deadline: October 15